OHR Pharmaceutical Inc (NASDAQ:OHRP)

Data as of Jan 30
 -0.37 / -4.70%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Ohr Pharmaceutical, Inc. operates as a biotechnology company, which is focused on the development of its acquired compounds. Its products include OHR/AVR 118 for the treatment of Cancer Cachexia and EVIZON, which are used for the treatment of the wet form of age related macular degeneration. The company was founded in 2008 and is headquartered in New York, NY.

Contact Information

Ohr Pharmaceutical, Inc.
489 5th Avenue
New York New York 10017
P:(212) 682-8452
Investor Relations:



Mutual fund holders6.56%
Other institutional28.98%
Individual stakeholders15.81%

Top Executives

Irach B. TaraporewalaPresident, Chief Executive Officer & Director
Samuel I. BackenrothChief Financial Officer & VP-Business Development
Glenn StollerChief Scientific Officer
Jason Scott SlakterDirector & Chief Medical Officer
Peter K. KaiserSenior Vice President-Product Development

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.